AI Summary & Key Takeaways
AI InsightBecause of the differences in many studies, risk factors for predicting the success of the treatment are not clear
📌 3 Key Takeaways
Abstract
OBJECTIVE: In this study, we aimed updating our experience about the treatment success of EMA-CO(etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) chemotherapy in high-riskgestational trophoblastic neoplasia (GTN).MATERIAL AND METHOD: Patients were scored according to FIGO's modified WHO system. Riskscoring of patients before 2000 was remade by using this system. Thirty-nine patients who were treatedwith EMA-CO between 1992 and 2013 because of high risk GTN or the resistance to single agentmethotrexate and MAC III chemotherapy combinations were evaluated retrospectively. Adjuvant surgeryand radiotherapy were used in selected patients. Response and effects of the prognostic factors to theresponse rate were analyzed.RESULTS: Median follow-up time of the patients was 74.8 months . Complete clinical response was obtained in 36 (92.3%) patients with only EMA-CO or EMA-CO and surgery. The responserate of treatment was 91.3% (n:21/23) in patients taking primary EMA-CO, 93.8% (n:15/16) in patientstaking secondary EMA/CO chemotherapy. Resistance to the EMA-CO treatment developed in 6 (15.3%)patients and 3 of the patients with drug resistance died. During the follow-up time disease recurred in 3(7.7%) patients. When the antecedent pregnancy was term pregnancy or the histopathological diagnosis was choriocarcinoma or when there was liver metastasis, the treatment success decreased. The effects of tumor dimension and the presence of metastasis tended to be statistically significant in determining the resistance to therapy. CONCLUSION: EMA-CO regimen is highly effective for treatment of high-risk GTN. Because of the differences in many studies, risk factors for predicting the success of the treatment are not clear
Özet
Bu çalışmamızda yüksek riskli gestasyonel trofoblastik neoplazide (GTN) EMA-CO (etoposid, metotreksat, aktinomi- sin-D, siklofosfamid, vinkristin) kemoterapisi hakkındaki dene- yimlerimizi güncellemeyi amaçladık.